MAFLD: Now is the time to capitalize on the momentum

Eslam, Mohammed; George, Jacob

doi:10.1016/j.jhep.2021.02.002

Cited by 10 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Capitalizing on this momentum with the more widespread use of the MAFLD criteria could result in even greater improvements in the care of MAFLD patients. 80…”

Section: Improve D Is E a S E Awarene Ssmentioning

confidence: 99%

See 1 more Smart Citation

The paradigm shift from NAFLD to MAFLD: A global primary care viewpoint

Farahat

Ungan

Vilaseca

et al. 2022

Liver International

View full text Add to dashboard Cite

“…Capitalizing on this momentum with the more widespread use of the MAFLD criteria could result in even greater improvements in the care of MAFLD patients. 80…”

Section: Improve D Is E a S E Awarene Ssmentioning

confidence: 99%

“…This demonstrates the success of the MAFLD criteria in the context of routine clinical care despite moderate adoption and suggests that the results are generalizable. Capitalizing on this momentum with the more widespread use of the MAFLD criteria could result in even greater improvements in the care of MAFLD patients 80 …”

Section: Improve Disease Awarenessmentioning

confidence: 99%

The paradigm shift from NAFLD to MAFLD: A global primary care viewpoint

Farahat

Ungan

Vilaseca

et al. 2022

Liver International

View full text Add to dashboard Cite

“…Nevertheless, individuals will persist in questioning the very existence of agreement. While time will be the final arbiter, we believe that the research energy should now be re‐directed towards building on the momentum generated by the controversy to improve the lives of people afflicted by MAFLD in all its myriad manifestations and enhance the assessment of alcohol use disorder (AUD) within alcohol‐related liver disease (ALD) 51 …”

Section: Introductionmentioning

confidence: 99%

The NAFLD‐MAFLD debate: Is there a Consensus‐on‐Consensus methodology?

Fouad

Dufour²,

Zheng

et al. 2022

Liver International

View full text Add to dashboard Cite

Polarizing opinions have recently arisen in hepatology on the name and redefinition of fatty liver disease associated with metabolic dysfunction. In spite of growing and robust evidence of the superior utility of the term metabolic (dysfunction) associated fatty liver disease (MAFLD) definition for clinical and academic practice, controversy abounds. It should therefore come, as no surprise that the most common arguments used in contrarian op‐eds is that there are no consensus on any name change. In this context, we suggest that discourse on an accurate understanding of what scientific consensus means, the various methods of achieving consensus, as well as other alternative models for reaching agreement is pivotal for the field. In this opinion piece, we provide an overview of these aspects as it applies to the case of fatty liver disease. We provide evidence that consensus on a change from non‐alcoholic fatty liver disease (NAFLD) to MAFLD has already been achieved. We believe that the time has come for redirecting stakeholder focus and energy on capitalizing on the momentum generated by the debate to improve the lives of people at its centre, our patients.

show abstract

“…Therefore, NAFLD has a place among the main public health problems. Since NAFLD is a multi-organ system disease [ 3 ] with a heterogeneous pathogenesis, experts have jointly proposed replacing it with metabolic-associated fatty liver disease (MAFLD) [ 4 ]. MAFLD is considered to be a clinicopathological syndrome characterised by hepatic steatosis, and it includes a continuum of hepatic conditions varying in the severity of injury and fibrosis, which is histologically defined as steatosis, inflammation, and ballooning of the hepatocytes [ 5 – 7 ].…”

Section: Introductionmentioning

confidence: 99%

Association of circulating vaspin levels and patients with metabolic-associated fatty liver disease: a systematic review and meta-analysis

Zhu

et al. 2022

Lipids Health Dis

View full text Add to dashboard Cite

Background The incidence rate of metabolic-associated fatty liver disease (MAFLD) is increasing annually; however, there are still no effective methods for establishing an early diagnosis and conducting real-time tracing. Vaspin can affect the metabolic processes in the body, and it is closely associated with many metabolic diseases. Many previous studies have speculated on the association between vaspin and MAFLD, but the results of these studies have not been conclusive. This meta-analysis examined the differences in circulating vaspin levels between patients with MAFLD and healthy individuals. Methods Six databases and other sources were searched with free terms and Medical Subject Headings terms, and a total of 13 articles were included (900 cases and 669 controls). RevMan 5.3 and Stata 16 were used for analysis. The standardised mean difference (SMD) and 95% confidence interval (CI) were used to assess the overall outcomes. Cohen’s kappa coefficient was applied to examine the differences between the two authors in the selection of studies and in the evaluation of the quality of evidence for the studies. Results The results demonstrated that there was no significant difference in the circulating vaspin levels between the MAFLD group and healthy group (SMD = 0.46, 95% CI: [− 0.12, 1.04]). The subgroup analysis suggested that area and body mass index (BMI) may be the sources of heterogeneity, and the results of univariate meta-regression analysis were consistent with those of the subgroup analysis (P = 0.005 and P < 0.001, respectively). Furthermore, BMI may better explain the source of heterogeneity (P = 0.032) in the multivariate meta-regression analysis. Conclusion In summary, no significant correlation was observed between the circulating vaspin levels and MAFLD. BMI may be an important factor affecting this correlation, which may provide a reference for further studies on mechanism and diagnosis of MAFLD.

show abstract

MAFLD: Now is the time to capitalize on the momentum

Cited by 10 publications

References 22 publications

The paradigm shift from NAFLD to MAFLD: A global primary care viewpoint

The paradigm shift from NAFLD to MAFLD: A global primary care viewpoint

The NAFLD‐MAFLD debate: Is there a Consensus‐on‐Consensus methodology?

Association of circulating vaspin levels and patients with metabolic-associated fatty liver disease: a systematic review and meta-analysis

Contact Info

Product

Resources

About